
HSCS Stock Forecast & Price Target
HSCS Analyst Ratings
Bulls say
HeartSciences Inc. is experiencing upward revisions in its FY26 earnings per share estimates, reflecting a positive adjustment due to a higher share count and improving business prospects. The anticipated approval of the MyoVista device, combined with the ongoing rollout of the MyoVista Insights cloud platform and the expected FDA approval of its first diagnostic algorithm in early 2026, positions the company for significant market potential. Additionally, the establishment of a new price target derived from net present value analysis indicates robust growth opportunities, suggesting a favorable outlook for the company's financial performance.
Bears say
HeartSciences Inc. is facing a significant downturn in its financial outlook, reflected in a dramatic decrease in projected revenue for FY2026, which has been revised down to $0.1 million from a previous estimate of $1.2 million due to FDA-related delays. Additionally, the company is burdened by substantial risks, including balance sheet and liquidity concerns, regulatory approval challenges, and competition in the healthcare sector. The combination of these operational setbacks and uncertainty in market conditions has contributed to a negative perspective on the company's potential for growth and financial stability.
This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.
HSCS Analyst Forecast & Price Prediction
Start investing in HSCS
Order type
Buy in
Order amount
Est. shares
0 shares